Assessing the Link Between Smoke Carcinogen Biomarkers and Lung Cancer Risk - 1
Lung cancer is the leading cause of cancer death in the United States. Currently it remains impossible to predict which smokers will get cancer. Each puff of a cigarette delivers a mixture of over 60 known carcinogens. Biomarkers that quantify carcinogen levels and metabolism are a useful tool and available to use. The purpose of this study is to assess the link between tobacco smoke carcinogen biomarkers and the risk of developing lung cancer.
Checked against the public recordLast updated Jan 23, 2017 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Not specified
- Study type
- Observational
- Phase
- Not applicable
- Sponsor
- University of Minnesota
- Interventions being studied
- Other: Non-intervention
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Screening arm participants in the Prostate, Lung, Colon, and Ovarian Screen Trial (PLCO) * Reported smoking on baseline questionnaire of PLCO * Contributed biorepository samples Exclusion Criteria: * Unstable physical or mental health
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- University of MinnesotaMinneapolis, Minnesota
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Jan 23, 2017. Always confirm current availability with the study team.